Evidence map›Paper›PMID 32183732›Full record

ArticleBMC cancer2020

Different ODE models of tumor growth can deliver similar results.

James A Koziol, Theresa J Falls, Jan E Schnitzer

Abstract read
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

James A KoziolProteogenomics Research Institute for Systems Medicine (PRISM), La Jolla, California, 92037, USA. JKoziol@prism-sd.org.ORCID http://orcid.org/0000-0002-0009-7987
Theresa J FallsProteogenomics Research Institute for Systems Medicine (PRISM), La Jolla, California, 92037, USA.
Jan E SchnitzerProteogenomics Research Institute for Systems Medicine (PRISM), La Jolla, California, 92037, USA.

Funding

Targeting TGF-b Inhibitors and PPAR-y Agonists To Enhance IPF TherapyP01HL119165 · NHLBI · PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED · PI BOROK, ZEA · 2015 to 2019
$13.6M
Tumor Imaging CoreP01CA221775 · NCI · PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED · PI SCHNITZER, JAN EUGENIUSZ · 2019 to 2023
$13.2M
Targeting Caveolae in Breast TumorsR01CA083989 · NCI · SIDNEY KIMMEL CANCER CENTER · PI SCHNITZER, JAN EUGENIUSZ · 2002 to 2006
$2.2M
Targeting Caveolae in Breast TumorsU01CA193787 · NCI · PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED · PI SCHNITZER, JAN EUGENIUSZ · 2015 to 2019
$2.0M
Nanodelivery to enhance the imaging and therapy of breast cancerR01CA169644 · NCI · PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED · PI SCHNITZER, JAN EUGENIUSZ · 2015 to 2018
$1.7M
Nanodelivery to enhance the imaging and therapy of breast cancerU01CA169644 · NCI · PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED · PI SCHNITZER, JAN EUGENIUSZ · 2019 to 2019
$410k
National Institutes for Water Resources (US) 1PO1HL119165NCI NIH HHS P01 CA221775NCI NIH HHS R01 CA083989NCI NIH HHS R01 CA169644NCI NIH HHS U01 CA169644NCI NIH HHS U01 CA193787NHLBI NIH HHS P01 HL119165
6 · The paper itself

Abstract

backgroundSimeoni and colleagues introduced a compartmental model for tumor growth that has proved quite successful in modeling experimental therapeutic regimens in oncology. The model is based on a system of ordinary differential equations (ODEs), and accommodates a lag in therapeutic action through delay compartments. There is some ambiguity in the appropriate number of delay compartments, which we examine in this note.

methodsWe devised an explicit delay differential equation model that reflects the main features of the Simeoni ODE model. We evaluated the original Simeoni model and this adaptation with a sample data set of mammary tumor growth in the FVB/N-Tg(MMTVneu)202Mul/J mouse model.

resultsThe experimental data evinced tumor growth heterogeneity and inter-individual diversity in response, which could be accommodated statistically through mixed models. We found little difference in goodness of fit between the original Simeoni model and the delay differential equation model relative to the sample data set.

conclusionsOne should exercise caution if asserting a particular mathematical model uniquely characterizes tumor growth curve data. The Simeoni ODE model of tumor growth is not unique in that alternative models can provide equivalent representations of tumor growth.

Indexed as

Models, BiologicalAlgorithmsAnimalsFemaleMammary Neoplasms, ExperimentalMiceCancer chemotherapyDelay differential equationsMathematical modelOrdinary differential equationsTumor growth

Identifiers

PMID32183732
PMCPMC7076937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.